Royal Philips has received approval from the the Food and Drug Administration to offer a medical digital imaging technology that is designed to electronically evaluate treatment methods for patients with breast cancer.
The Her2/neu IHC Digital Manual Read is also built to automatically create digital slides and display them on a computer monitor for pathologists, Philips said Wednesday.
“Clinical pathologists will now have direct access to the digitally stored Her2/neu IHC images to help them in the detection and semi-quantitative measurement of immunohistochemically (IHC) stained breast cancer tissue on their computer monitor,” said Perry van Rijsingen, general manager at Philips Digital Pathology.
The system has been commercially available in the Asia-Pacific region and Europe since 2012.
“Digitalization will continue to revolutionize healthcare by providing the right clinical information to the right caregiver at the right time,” van Rijsingen said.